Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

2016-08-01

Gleeson, Mary

Hawkes, Eliza A

Cunningham, David

Chadwick, Nick

Counsell, Nicholas

Lawrie, Anthony

Jack, Andrew

Smith, Paul

Mouncey, Paul

Pocock, Christopher

Ardeshna, Kirit M

Radford, John

McMillan, Andrew

Davies, John

Turner, Deborah

Kruger, Anton

Johnson, Peter WM

Gambell, Joanna

Linch, David

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Lymphoma, B-Cell

Rituximab

Cyclophosphamide

Doxorubicin

Vincristine

Prednisolone

Journal Article

10.1111/bjh.14287

We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

link

British Journal of Haematology 2016; online first: 1 August

British Journal of Haematology